Jefferies Raises Price Target on Cubist (CBST) to $55

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Jefferies reiterated a Buy rating on Cubist Pharmaceuticals (NASDAQ: CBST) and raised its price target to $55.00 (from $52.00).

Cubist it has 3 products in Ph3 development and analyst said they believe the stock is attractive based on the pipeline products potential.

"Our $55 PT is based on a sum-of-parts NPV analysis of a fair value of $49/sh for Cubicin, $5/sh for CXA-201 (65% probability-adjusted) and $1 for Entereg using an 11% annual discount rate," said analyst Eun K. Yang.

For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.

Shares of Cubist Pharmaceuticals closed at $47.25 yesterday, with a 52 week range of $34.58-$49.86.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
• KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
• Jefferies Bumps PT on Home Depot (HD) to $91

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?